Haleon plc (HLN)
LSE
Real-time Data
07:00 AM
Day's Range
358.1052 wk Range
274.40Overview - HLN - Haleon plc
Key Statistics
Valuation
Enterprise Value
39.74B
P/E (Trailing)
‪20.17‬
P/E (Forward)
‪15.83‬
PEG Ratio
‪15.83‬
Price / Sales (TTM)
‪2.86‬
Price / Book
‪196.90‬
EV / EBITDA
‪13.95‬
Profitability
Gross Margin
‪55.38%‬
Profit Margin
‪14.55%‬
Operating Margin
‪23.93%‬
Return on Assets
‪5.08%‬
Return on Equity
‪10.09%‬
Ownership
Shares Outstanding
8.90B
Float
8.85B
Held by Insiders
‪0.06%‬
Held by Institutions
‪59.38%‬
Price stats
Beta
‪0.24‬
50-Day Avg
‪357.98‬
200-Day Avg
‪363.94‬
Dividends
Payout Ratio
‪39.23%‬
Frequency
Semi-Annual
Analyst Consensus
18 analysts
Average price target
‪£ 420.82‬Shariah Compliance
Report Date: Feb 20, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - HLN - Haleon plc
Peers - HLN - Haleon plc
Peer Comparison
Compared with companies in Drug Manufacturers - Specialty & Generic listed on LSE.
Profile Summary - HLN - Haleon plc
About
Haleon plc is a global consumer health company focused on over-the-counter products that address everyday health needs. Headquartered in the United Kingdom, Haleon operates across key categories such as oral health, pain relief, respiratory health, digestive wellness, and vitamins, minerals and supplements. Its…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
